Technical Analysis for INKT - MiNK Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
20 DMA Support | Bullish | -0.70% | |
Hammer Candlestick | Bullish | -0.70% | |
Doji - Bullish? | Reversal | -0.70% | |
Overbought Stochastic | Strength | -0.70% | |
Down 3 Days in a Row | Weakness | -0.70% | |
50 DMA Resistance | Bearish | -1.66% |
Alert | Time |
---|---|
20 DMA Resistance | about 18 hours ago |
10 DMA Resistance | about 18 hours ago |
Fell Below 20 DMA | about 18 hours ago |
20 DMA Support | about 21 hours ago |
Hammer Candlestick Entry | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.9 |
52 Week Low | 0.57 |
Average Volume | 34,724 |
200-Day Moving Average | 0.89 |
50-Day Moving Average | 0.74 |
20-Day Moving Average | 0.70 |
10-Day Moving Average | 0.72 |
Average True Range | 0.04 |
RSI (14) | 46.81 |
ADX | 23.14 |
+DI | 12.60 |
-DI | 19.29 |
Chandelier Exit (Long, 3 ATRs) | 0.64 |
Chandelier Exit (Short, 3 ATRs) | 0.69 |
Upper Bollinger Bands | 0.75 |
Lower Bollinger Band | 0.65 |
Percent B (%b) | 0.61 |
BandWidth | 13.59 |
MACD Line | -0.01 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0057 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.78 | ||||
Resistance 3 (R3) | 0.78 | 0.75 | 0.77 | ||
Resistance 2 (R2) | 0.75 | 0.73 | 0.76 | 0.77 | |
Resistance 1 (R1) | 0.73 | 0.72 | 0.74 | 0.73 | 0.76 |
Pivot Point | 0.70 | 0.70 | 0.71 | 0.71 | 0.70 |
Support 1 (S1) | 0.68 | 0.69 | 0.69 | 0.68 | 0.66 |
Support 2 (S2) | 0.65 | 0.67 | 0.66 | 0.65 | |
Support 3 (S3) | 0.63 | 0.65 | 0.65 | ||
Support 4 (S4) | 0.63 |